Who writes here
Every blog post and policy page on cannabless.org is authored by the CannaBless Editorial team. Drafts are written by the team, often informed by Claude (Anthropic) for first-pass structure and language, and then human-edited end to end before publication. Nothing is published from a generated draft without that editing pass.
What we cite
Our regulatory and operational claims trace to primary sources: the Therapeutic Goods Administration (Australia), the Federal Institute for Drugs and Medical Devices (BfArM, Germany), the Israeli Medical Cannabis Agency (IMC), the Department of Thai Traditional and Alternative Medicine, Health Canada, and EU regulatory texts. Where a piece references a clinical or pharmacological claim, the underlying primary literature is consulted before publication.
We don’t publish unsupported claims. If a sentence on a CannaBless page asserts a regulatory fact, a chemistry fact, or a clinical fact, the editorial team holds the source for it.
Editorial review
Posts that touch on medical, regulatory, or clinical material pass through editorial review by a clinically credentialed reviewer (medical degree, active licence, no public professional profile by reviewer’s preference) before publication. The reviewer checks regulatory accuracy, clinical plausibility, and the absence of patient-facing medical advice.
The reviewer does not provide individual clinical recommendations and is not authoring patient-care guidance. Their scope is the accuracy and proper framing of B2B regulatory and operational content.
What we don’t do
- We do not give patients medical advice. Every page on the site is written for licensed importers, regulators, journalists, and clinical-research collaborators — not for patients evaluating their own treatment.
- We do not promote cannabis use. We describe regulatory pathways through which licensed prescribers may prescribe medical cannabis under defined indications.
- We do not write claims we can’t source. If we make a regulatory or clinical assertion, the editorial team holds the supporting source.
- We do not auto-publish AI-generated content. Drafts that originate with Claude pass through human editing and (for medical content) clinical review before publication.
Corrections
If you spot a factual error, a regulatory mischaracterisation, or a passage that reads as medical advice when it shouldn’t, please write to contact@cannabless.org. Substantive corrections are made within one business week and the post’s updated date is bumped to reflect the change.
Conflicts of interest
CannaBless is a B2B medical-cannabis exporter that supplies licensed importers in Australia, Germany, Israel, and Switzerland. Our content has a commercial interest in painting the regulated medical-cannabis supply chain accurately and rigorously. We believe that interest aligns with our editorial discipline rather than conflicting with it: our customers are themselves regulators-of-suppliers, and our content is read by regulators, so loose claims would damage both reputation and supply.
We do not accept paid placements, sponsored content, or guest posts.
Why some bylines are anonymous
Where a contributor or reviewer is identified by initials or by role rather than full name, that’s at their request. Many of our clinical reviewers operate in jurisdictions where being publicly associated with a cannabis brand has career consequences disproportionate to the editorial role. We respect that and accept the opacity cost as the right tradeoff for now.
If a reader requires more detail on a specific reviewer’s credentials for a regulatory or institutional purpose, please reach contact@cannabless.org and we’ll consider direct verification on a case-by-case basis.
This page
Last reviewed . Material changes to editorial process are reflected here as they happen; minor corrections are made silently.